What is Stockpools?

Need an account?

Play for free for a chance to win.

Join the Stockpools community today

Register now

Stockpools on your Phone

Follow Stockpools

3D Signatures Announces Completion of Stage 3 of Hodgkin’s Lymphoma Test Validation Prgrm


3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0), is pleased to announce that, on September 30, 2017, the Company completed the clinical trial component (the “Clinical Trial”), or Stage 3, of its Hodgkin’s lymphoma (“HL”) test (“Telo-HLTM”) validation program. Data from the Clinical Trial has been submitted to the Company’s statistics consulting partner for analysis.

“We are excited to accomplish this critical milestone on schedule, and we remain on track for the expected commercial launch of Telo-HLTM as an LDT by the end of Q1 2018,” commented Jason Flowerday, CEO of 3DS.

Click here to read the original article.